Welcome To COVIDSurg3

A new study on the outcomes of patients with perioperative SARS-CoV-2 infection

during the vaccination and Omicron era

COVIDSurg3 is an international prospective cohort study aiming to:

(1) Determine 30-day mortality in patients with peri-operative SARS-CoV-2 infection

(2) Inform future risk stratification, decision making and patient consent

ANY hospital can participate

ALL collaborators will be included as PubMed-citable co-authors on resulting publications

Hospitals can participate in the patient-level component, the hospital-level component, or ideally both

Patient-level component


Assess the outcomes of patients with peri-operative SARS-CoV-2 and evaluate implementation of SARS-CoV-2 adaptations.


  • Surgery performed by a surgeon in an operating theatre AND
  • A positive SARS-CoV-2 PCR swab or rapid antigen test within 7 days before or 30 days after surgery


All eligible patients across all specialties should be captured for at least 4 weeks between 13 December 2021 to 28 February 2022


  • 1 hospital lead (for both components)
  • Up to 5 total collaborators to collect data

Hospital-level component


Determine the frequency of perioperative SARS-CoV-2 infection and same-day elective cancellations


  • Any hospital can participate, regardless of taking part in the patient level component.
  • Data collection must be mapped to one or more of the pre-defined body regions specified in the protocol.


All elective and emergency surgical activity relating to the selected body region(s) should be captured during one or more of the 14 day blocks.


  • 1 hospital lead (for both components)
  • One collaborator per 14-day block, collecting data for one or more specialities
  • Maximum of 4 collaborators per body region

COVIDSurg3 documents

Study protocol
Patient-level component data sheet
Hospital-level component data sheet
Protocol appendix
REDCap guide
Patient cross list